Annual Report 2021
A year in review
2021 has been a year filled with challenges, but also one during which we have made encouraging advances. Thanks to the hard work and unfailing professionalism of our teams, we continue to pioneer and launch new treatments which will significantly improve our patients’ lives. We have our eyes firmly set on the future as we continue to build upon our portfolio, strengthening our position in the field of Medical Dermatology. During 2021, we invested more than €73 million euros into our R&D projects. This has enabled us to continue to develop innovative medical solutions which will improve patients’ lives on a daily basis and also positively impact healthcare professionals across the world.
To download the Annual Report 2021 click here
Financial Results
€836.5 MM
Total Revenues
€827.2 MM
Net Sales
€81.4 MM
Normalised Net Income
€235.6 MM
EBITDA
€233.8 MM
Operating Cash FlowInterviews
Dr. Volker Koscielny
Chief Medical Officer, Almirall
Dr. Karl Ziegelbauer
Chief Scientific Officer, Almirall
Prof. Dr. Matthias Augustin
Director, Institute of Health Care Research in Dermatology and Nursing, University of Hamburg
Patient story: Christina
Living with psoriasis
Driving our R&D
- €73.6 MM in R&D Investment- R&D : 9% over Net Sales
Environment
- CO2 emissions Scope 1&2 (location-based): 11,458 ton (-10% vs 2020)- Waste Management: 5,390 ton (-4% vs 2020)- CDP Climate Change Score in 2021: B level Management
Social
1,786Number of employees
53%Women
47%Men
26Nationalities represented
19,297Total training hours
Net Sales by geographic area
82%Europe
11%US
7%Rest of the world
Our commitment
Deliver Medical Dermatology solutions that impact patients' lives
Enhance our focus on innovation by investing in transformative therapies that meet patients’ needs
Solidify Almirall as a global leader in Medical Dermatology
Reduction of our carbon footprint and mitigation of climate change's effect